Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

14.32 -0.25 (-1.72%)
Delayed Quote Updated: 1:13 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy ↗
HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The... 
Via MarketBeat
News headline image
HUTCHMED H1 Earnings Call Highlights ↗
HUTCHMED (NASDAQ:HCM) reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported... 
Via MarketBeat
Topics Earnings
News headline image
IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics ↗
China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma. 
Via Stocktwits
News headline image
Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength ↗
Hutchmed forecasts 2025 oncology revenue of $350–$450 million after a strong 65% growth in 2024, driven by Fruzaqla sales and new regulatory approvals in China. 
Via Benzinga
News headline image
Earnings Scheduled For March 19, 2025 ↗
 
Via Benzinga
News headline image
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million ↗
Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including clinical trials by 2025. 
Via Benzinga
News headline image
Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Hutchmed scores U.S. success with cancer drug, but profits still dip ↗
Key Takeaways: Hutchmed’s U.S. sales jumped nearly 53% in the second quarter from the previous three months, boosted by uptake of the cancer drug Fruzaqla The company plans to focus on innovative drugs... 
Via Benzinga
News headline image
Why HUTCHMED Stock Is Moving Higher Friday ↗
HUTCHMED announced that its New Drug Application for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status. 
Via Benzinga
News headline image
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
News headline image
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket ↗
Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
News headline image
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning! 
Via InvestorPlace
News headline image
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. 
Via Benzinga
News headline image
Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 80 points on Wednesday. 
Via Benzinga
News headline image
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets ↗
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones. 
Via Talk Markets
News headline image
Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know ↗
 
Via Benzinga
News headline image
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier. 
Via Investor's Business Daily
News headline image
Rocket Pharmaceuticals Stock Sees Improved Price Strength ↗
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
News headline image
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher ↗
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.